On the Radar…

AmideBio announced that it has closed a $575,000 preferred equity financing round. The source of the funds was not disclosed. AmideBio uses proprietary “Cap-Clip” technology, exclusively licensed from the University of Colorado, to produce and commercialize technically challenging peptides. This technology has the potential to both lower costs and improve purity in peptide manufacturing. This new manufacturing process has applicability in both the research and therapeutics market. To date, AmideBio has produced research grade peptides with its technology, and the company has biosimilars and therapeutic peptides in development. The funds will be used to continue optimization of multiple peptide products. AmideBio is based in Boulder, Colorado.